Psoriasis: Advances in pathophysiology and management

Postgraduate Medical Journal

Volumn 83, Issue 985, 2007, Pages 690-697

  MacDonald, A ^a   Burden, A D ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; BETAMETHASONE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DIMETHYLFUMARATE; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOMETHYLFUMARATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RETINOID; SALICYLIC ACID; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; GASTROINTESTINAL SYMPTOM; GENOTYPE; HAIR LOSS; HUMAN; HYPERTENSION; INFECTION; LIVER FIBROSIS; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHOMA; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; PATHOPHYSIOLOGY; PERIORAL DERMATITIS; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN IRRITATION; TACHYPHYLAXIS; TERATOGENICITY; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; GENOTYPE; HUMANS; IMMUNOTHERAPY; PSORIASIS; PUVA THERAPY; STEROIDS;

EID: 36749053497     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.061473     Document Type: Review

References (72)

1. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
2. Lebwohl M, Callen JP. Obesity, smoking and psoriasis. JAMA 2006;295:208-10.
3. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
4. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
5. Prodanowich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
6. Boffeta P. Cancer risk in a population-based cohort of patients hospitalised for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7.
7. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90.
8. Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9.
9. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's and ulcerative colitis. Br J Dermatol 1982;106:323-30.
10. Ho P, Bruce IN, Silman A, et al. Evidence for common genetic control pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602.
11. Woodruff PWR, Higgins EM, du Vivier AWP, et al. Psychiatric illness in patients referred to a dermatology-psychiatry clinic. Gen Hosp Psychiatry 1997;19:29-35.
12. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50.
13. Gupta MA, Gupta AK. Psychodermatology: an update. J Am Acad Dermatol 1996;34:1030-46.
14. Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005;152:861-7.
15. Ashcroft DM, Li Wan Po A, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185-91.
16. Lewis V, Finlay AY. Ten years of experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004;9:169-80.
17. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:659-64.
18. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-34.
19. Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001;18:188-98.
20. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence of further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:81-20.
21. Burden AD, Javed S, Bailey M, et al. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 1998;110:958-60.
22. Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism based map defines genetic variation at PSORS 1, the major psoriasis susceptibility locus. Am J Hum Genet 2002;71:554-64.
23. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility gene. Am J Hum Genet 2006;78:827-51.
24. Helms C, Saccone NL, Cao L, et al. Localisation of PSORS 1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 2005;118:466-76.
25. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C and HLA-B typed patients. J Invest Dermatol 2006;126:740-5.
26. Hwu WL, Young CF, Fann CSJ, et al. Mapping of psoriasis to 17q terminus. J Med Genet 2005;42:152-8.
27. Cookson WO, Ubbhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001;27:372-3.
28. Thompson SD, Moroldo MB, Guyer, et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 2004;50:2920-30.
29. Low JH, Williams FA, Yang X, et al. Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis 2004;10:173-81.
30. Zenz R, Erfel R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
31. Creamer D, Allen MH, Sousa A, et al. Localisation of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997;136:859-65.
32. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.
33. Creamer D, Allen MH, Groves RW, et al. Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 1996;348:1101.
34. Bhushan M, McLaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:851-5.
35. Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002;138:791-6.
36. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 1997;137:130-2.
37. Boyman O, Hefti HP, Conrad C, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumour necrosis factor-alpha. J Exp Med 2004;199:731-6.
38. Kauffman CL, Aria N, Toichi E, et al. A phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:125-30.
39. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin 22 a T(H)17 cytokine, mediates IL-23 dermal inflammation and acanthosis. Nature 2007;445:648-51.
40. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque type psoriasis. J Biol Regul Homeost Agents 1997;11:115-8.
41. Cameron AL, Kirby B, Grifffiths CE. Circulating natural killer cells in psoriasis. Br J Dermatol 2003;149:160-4.
42. Baker BS, Ovigne JM, Powles AV, et al. Normal keratinocytes express toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003;148:670-9.
43. Litjens NH, Rademaker M, Ravensbergen B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in downregulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565-75.
44. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006;126:453-9.
45. Berkun Y, Levartovsky D, Rubinow A, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-31.
46. Van Ede AE, Laan RF, Blom HJ, et al. The C667T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
47. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systemic review. Br J Dermatol 2002;146:351-64.
48. Guenther L, van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double blind, vehicle controlled clinical trial. Br J Dermatol 2002;147:316-2.
49. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30.
50. Gordon PM, Diffey BL, Matthews JNS, et al. A randomized comparison of narrowband TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32.
51. Cameron H, Dawe RS, Yule S, et al. A randomized, observer-blinded trial of twice versus three times weekly narrowband UVB phototherapy for chronic plaque psoriasis. Br J Dermatol 2002;147:973-8.
52. Pasker de Jong PC, Wieling G, van der Valk PG, et al. Treatment with UVB for psoriasis and non-melanoma skin cancer: a systemic review of the literature. Arch Dermatol 1999;135:834-40.
53. Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatoloy Group Workshop Report. Br J Dermatol 2004;151:283-97.
54. Lauharanta J. Photochemotherapy. Clin Dermatol 1997;15:769-80.
55. Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998;134:595-8.
56. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125.
57. Nijsten TEC, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003;121:252-8.
58. Leon A, Nguyen A, Letsinger J, et al. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007;8:617-32.
59. National Patient Safety Agency. http://www.npsa.nhs.uk (Accessed 4 April 2007).
60. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
61. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis an psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991;25:50-3.
62. Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169-74.
63. Heydendael VM, Spuls PI, Opmeeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
64. Naldi L, Rzany B. Chronic plaque psoriasis. Clin Evid 2002;8:1688-708.
65. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
66. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efaluzimab, for chronic plaque psoriasis. N Engl J Med 2003;349:2004-13.
67. Gordon KB, Papp KA, Hamilton TK, et al. Efaluzimab for patients with moderate-to severe plaque psoriasis; a randomized controlled trial. JAMA 2003;232:3073-80.
68. Krueger GG, Papp KA, Slough DB, et al. A randomized, double-blind, placebo-controlled phase III stucly evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
69. Gordon KB, Papp KA, Hamilton TK, et al. Efaluzimab for patients with moderate-to severe plaque psoriasis; a randomized controlled trial. JAMA 2003;232:3073-80.
70. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate-to-severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
71. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014-22.
72. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.